Related Experiment Video

Updated: Sep 12, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage

Chuanhua Zhao1, Yanqiao Zhang2, Gang Wang3

  • 1Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.

Signal Transduction and Targeted Therapy
|August 6, 2025
PubMed

Insights

First-line treatment with finotonlimab plus SCT510 (bevacizumab biosimilar) significantly improved progression-free survival and overall survival in patients with unresectable advanced hepatocellular carcinoma (HCC) compared to sorafenib.

Area of Science:

  • Oncology
  • Immunotherapy
  • Hepatocellular Carcinoma Research

Background:

  • Unresectable advanced hepatocellular carcinoma (HCC) remains a significant clinical challenge with limited first-line treatment options.
  • Sorafenib has been a standard first-line treatment, but outcomes can be improved.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of finotonlimab (anti-programmed cell death protein-1 antibody) combined with SCT510 (bevacizumab biosimilar) as a first-line treatment for unresectable advanced HCC.
  • To compare this combination therapy against sorafenib in a randomized phase 2/3 study.

Main Methods:

  • A randomized phase 2/3 study involving 398 HCC patients in China.
  • Phase 3 randomized 346 patients to either finotonlimab plus SCT510 (dual-agent) or sorafenib.
  • Median follow-up was approximately 19-20 months, with efficacy assessed by blinded independent central review (BICR) using RECIST 1.1 criteria.

Main Results:

  • The dual-agent group showed significantly longer median progression-free survival (PFS) (7.1 months vs. 2.9 months; HR: 0.5; p < 0.0001).
  • Median overall survival (OS) was also significantly longer in the dual-agent group (22.1 months vs. 14.2 months; HR: 0.60; p < 0.0008).
  • The combination therapy demonstrated a manageable safety profile.

Conclusions:

  • Finotonlimab in combination with SCT510 (bevacizumab biosimilar) is an effective first-line treatment for unresectable advanced HCC.
  • This dual-agent therapy offers a significant survival benefit over sorafenib.
  • The combination presents a favorable efficacy and safety profile for HCC management.

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.4K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

599

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K